logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
10/27/2020 10:28:52 PM Ultragenyx Pharma Q3 Loss Narrows
10/27/2020 4:20:41 PM Ultragenyx Q3 Net Loss $68.8 Mln Or $1.13/Shr Vs Loss $113.0 Mln Or $1.96/Shr Last Year
9/2/2020 8:14:42 AM Ultragenyx Appoints Mardi Dier As CFO
9/1/2020 8:37:44 AM Ultragenyx Appoints Ernie Meyer As EVP And Chief Human Resources Officer
7/30/2020 5:13:09 PM Ultragenyx Pharma Q2 EPS $0.41 Vs. Loss $1.72 Year Ago
7/22/2020 8:40:59 AM Ultragenyx Announces U.S. Commercial Launch Of Dojolvi For The Treatment Of Long-chain Fatty Acid Oxidation Disorders
5/6/2020 4:59:17 PM Ultragenyx Pharma Q1 Loss/share $2.05 Vs. Loss $1.82 Year Ago
3/16/2020 8:42:53 AM GeneTx And Ultragenyx Report First Patient Dosed In Phase 1/2 Clinical Trial Of GTX-102
2/13/2020 4:05:02 PM Ultragenyx Pharma Q4 Loss/share $1.62 Vs. Loss $1.73 Year Ago
12/18/2019 8:38:25 AM Ultragenyx Reports Sale Of Future European Royalties On Crysvita For $320 Mln To Royalty Pharma
10/14/2019 8:45:11 AM Ultragenyx Says FDA Accepted For Review NDA For UX007
9/3/2019 8:35:03 AM GeneTx And Ultragenyx: FDA Grant Orphan Drug Designation And Rare Pediatric Disease Designation To GTX-102
8/1/2019 8:37:40 AM Ultragenyx Submits NDA For UX007 For Long-Chain Fatty Acid Oxidation Disorders
5/7/2019 9:21:54 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY19 Rev. Estimate To 95.1 M From 116.8 M
5/7/2019 9:21:42 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q4 19 Rev. Estimate To 30.4 M From 37.3 M